Sign in

    Cardio Diagnostics Holdings Inc (CDIO)

    Financials

    Updated Mar 29, 2025, 6:30 PM UTC
    Income Statement - MetricQ1 2022Q2 2022Q3 2022Q4 2022FY 2022Q1 2023Q2 2023Q3 2023Q4 2023FY 2023Q1 2024Q2 2024Q3 2024Q4 2024FY 2024
    Revenue (USD)10,030.005,310.0017,06515,9287,870.006,580.004,512.0034,890
    Sales and Marketing Expenses (USD)34,067.0043,288.00158,51434,40257,779.0052,059.0038,206.00182,446
    Research and Development Expenses (USD)38,708.007,492.00145,18210,8407,280.005,247.005,758.0029,125
    General and Administrative Expenses (USD)1,376,644.001,491,726.006,936,6464,123,9411,220,477.001,353,439.001,471,601.008,169,458
    Amortization (Operating Expenses) (USD)4,802.004,802.0019,1824,7934,794.004,802.005,349.0019,738
    Total Operating Expenses (USD)1,454,221.001,547,308.007,259,524(4,173,976)(1,290,330.00)(1,415,547.00)(1,520,914.00)(8,400,767)
    Loss from Operations (USD)(1,444,191.00)(1,541,998.00)(7,242,459)(4,158,048)(1,282,460.00)(1,408,967.00)(1,516,402.00)(8,365,877)
    Interest Income (USD)283.00301.001,068221342.00204.00297.001,064
    Interest Expense (USD)(570,385.00)(96,101.00)(6,735,013)(5,817)(5,817.00)(3,879.00)(3,127.00)(18,640)
    Total Other Income (Expenses) (USD)(488,191.00)153,069.00(1,134,375)(5,536)(5,535.00)(3,599.00)(2,906.00)(17,576)
    Loss Before Provision for Income Taxes (USD)(1,932,382.00)(1,388,929.00)(8,376,834)(4,163,584)(1,287,995.00)(1,412,566.00)(1,519,308.00)(8,383,453)
    Net Loss (USD)(1,932,382.00)(1,388,929.00)(8,376,834)(4,163,584)(1,287,995.00)(1,412,566.00)(1,519,308.00)(8,383,453)
    Net Loss per Common Share (USD)(0.15)0.00(0.66)(0.20)(0.05)(0.05)(0.01)(0.31)
    Weighted Average Common Shares Outstanding - Basic and Fully Diluted676,346.002,112,063.0012,685,13321,077,225765,197.00873,137.004,177,146.0026,892,705
    Balance Sheet - MetricQ1 2022Q2 2022Q3 2022Q4 2022FY 2022Q1 2023Q2 2023Q3 2023Q4 2023FY 2023Q1 2024Q2 2024Q3 2024Q4 2024FY 2024
    Cash (USD)3,629,6481,283,5231,283,5231,563,1391,310,1191,982,5907,827,4877,827,487
    Accounts Receivable (USD)3504,9604,96018,9887,52014,10018,61218,612
    Prepaid Expenses and Other Current Assets (USD)892,3001,477,1971,477,1971,007,147820,887630,482944,683944,683
    Total Current Assets (USD)4,522,2982,765,6802,765,6802,589,2742,138,5262,627,1728,790,7828,790,782
    Property and Equipment, Net (USD)37,233571,873571,873588,271720,175706,659672,861672,861
    Right of Use Assets, Net (USD)879,284575,227575,227555,270514,937473,984432,397432,397
    Intangible Assets, Net (USD)25,33321,33321,33317,33313,3339,3335,3335,333
    Deposits (USD)12,85012,85012,85012,85012,85012,85012,85012,850
    Patent Costs, Net (USD)486,309515,402515,402564,565596,944651,463701,089701,089
    Total Assets (USD)5,963,3074,462,3654,462,3654,327,5633,996,7654,481,46110,615,31210,615,312
    Accounts Payable and Accrued Expenses (USD)623,075243,213243,213224,71952,08174,80887,66187,661
    Lease Liability - Current (USD)178,066223,929223,929227,203230,515233,871237,270237,270
    Finance Agreement Payable (USD)-374,000374,000233,75093,500-306,764306,764
    Total Current Liabilities (USD)2,955,108841,142841,142685,672376,096308,679631,695631,695
    Lease Liability - Long Term (USD)720,468663,099663,099605,090546,433486,597425,829425,829
    Total Liabilities (USD)3,675,5761,504,2411,504,2411,290,762922,529795,2761,057,5241,057,524
    Common Stock (USD)131205205216233303459459
    Additional Paid-in Capital (USD)15,267,05117,326,29917,326,29921,568,54922,893,96224,918,40732,309,16232,309,162
    Accumulated Deficit (USD)(12,979,451)(14,368,380)(14,368,380)(18,531,964)(19,819,959)(21,232,525)(22,751,833)(22,751,833)
    Total Stockholders’ Equity (USD)2,287,7312,958,1242,958,1243,036,8013,074,2363,686,1859,557,7889,557,788
    Total Liabilities and Stockholders’ Equity (USD)5,963,3074,462,3654,462,3654,327,5633,996,7654,481,46110,615,31210,615,312
    Cash Flow - MetricQ1 2022Q2 2022Q3 2022Q4 2022FY 2022Q1 2023Q2 2023Q3 2023Q4 2023FY 2023Q1 2024Q2 2024Q3 2024Q4 2024FY 2024
    Net loss [USD](1,932,382.00)(1,388,929.00)(8,376,834)(4,163,584)(1,287,995.00)(1,412,566.00)(1,519,308.00)(8,383,453)
    Depreciation [USD]-2,413.003,7903,58735,992.0036,762.0037,436.00113,777
    Amortization [USD]38,848.0059,404.00107,83024,75045,127.0045,755.0046,936.00162,568
    Stock-based compensation expense [USD]72,000.0062,000.001,279,2732,519,40426,731.0022,618.0022,415.002,591,168
    Non-cash interest expense [USD]561,513.0092,224.006,704,522-----
    Change in fair value of derivative liability [USD]31,033.00195,832.00(5,406,220)-----
    Gain on extinguishment of debt [USD]--(193,350)-----
    NET CASH USED IN OPERATING ACTIVITIES [USD](1,044,599.00)(1,685,677.00)(5,672,175)(1,233,050)(1,210,400.00)(1,157,359.00)(1,392,295.00)(4,993,104)
    Purchases of property and equipment [USD](12,591.00)(537,053.00)(575,663)(19,985)(167,896.00)(23,246.00)(3,638.00)(214,765)
    Payments for right of use asset [USD]-0.00(21,352)-----
    Patent and trademark costs incurred [USD](53,127.00)(29,895.00)(197,276)(49,956)(33,173.00)(55,321.00)(50,975.00)(189,425)
    NET CASH USED IN INVESTING ACTIVITIES [USD](87,070.00)(566,948.00)(794,291)(69,941)(201,069.00)(78,567.00)(54,613.00)(404,190)
    Proceeds from sale of common stock and warrants [USD]---1,877,8571,298,699.002,001,897.007,368,496.0012,546,949
    Proceeds from convertible notes payable, net of original issue discount [USD]0.000.004,500,000-----
    Proceeds from exercise of warrants [USD]0.000.00390,000-----
    Payments of finance agreement [USD](283,011.00)(93,500.00)(942,532)(140,250)(140,250.00)(93,500.00)(76,691.00)(450,691)
    Payments of placement agent fee [USD]0.000.00(315,000)(155,000)0.000.000.00(155,000)
    NET CASH PROVIDED BY FINANCING ACTIVITIES [USD](283,011.00)(93,500.00)3,632,4681,582,6071,158,449.001,908,397.007,291,805.0011,941,258
    NET INCREASE (DECREASE) IN CASH [USD](1,414,680.00)(2,346,125.00)(2,833,998)279,616(253,020.00)672,471.005,844,897.006,543,964
    Interest paid [USD]8,871.003,878.0030,4915,8175,817.003,879.003,127.0018,640
    Debt discount related to derivative liability [USD]0.000.005,000,000-----
    Notes payable converted to common stock [USD]1,150,000.001,700,000.005,000,000-----
    Adjustment to liabilities assumed in acquisition [USD]0.000.0074,025-----
    Financing agreement entered into for prepaid insurance [USD]--467,500----383,455
    Accounts receivable [USD](350)(4,960)(4,960)(14,028)(2,560)(9,140)(13,652)(13,652)
    Prepaid expenses and other current assets [USD]876,066758,669758,669470,050656,310846,715915,969915,969
    Deposits [USD](7,900)(7,900)(7,900)-----
    Accounts payable and accrued expenses [USD](401,638)(781,500)(781,500)(18,494)(191,132)(168,405)(155,552)(155,552)
    Lease liability [USD]6,556244,505244,505(54,735)(110,080)(166,560)(223,929)(223,929)
    CASH – BEGINNING OF YEAR [USD]4,117,5214,117,5214,117,5211,283,5231,283,5231,283,5231,283,5231,283,523
    CASH – END OF YEAR [USD]3,629,6481,283,5231,283,5231,563,1391,310,1191,982,5907,827,4877,827,487
    Right of use asset added for operating lease [USD]891,978642,523642,523-----
    Revenue by Segment - in Millions of USDQ1 2022Q2 2022Q3 2022Q4 2022FY 2022Q1 2023Q2 2023Q3 2023Q4 2023FY 2023Q1 2024Q2 2024Q3 2024Q4 2024FY 2024
    - Telemedicine platform--------
    - Provider organizations--------
    - Employers--------
    Total Revenue0.0100.010.0170.0167.870.006582734.89
    KPIs - Metric (Unit, Scale)Q1 2022Q2 2022Q3 2022Q4 2022FY 2022Q1 2023Q2 2023Q3 2023Q4 2023FY 2023Q1 2024Q2 2024Q3 2024Q4 2024FY 2024
    Number of new provider organizations (count)-------7